$SNEX

Thamodaran Dhamu R. purchased $161K of SNEX (indirect holdings)

Thamodaran Dhamu R. purchased 2,500 indirectly-held shares of StoneX Group Inc. (SNEX) at $64.48 ($0.16M total) on 2026-08-10.

Original reporting
SEC EDGAR · Thamodaran Dhamu R.
Published Aug 11, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Bullish
low confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXBullishLow
01

Why it matters

The only actionable new fact is the disclosed insider buy (2,500 shares at $64.4824) and the post-transaction share count (75,760).

02

Market read

Traders may note the insider purchase as a small sentiment input, but there is no accompanying fundamental update in the filing text.

03

What to watch

The purchase is indirect and there is no 10b5-1 plan, but the article does not clarify whether this is part of a broader pattern of buys/sells or tax/estate-related activity.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-11, transaction dated 2026-08-10.

Background

This is an SEC Form 4 insider transaction disclosure for StoneX Group Inc.

Company-level read

Ticker impact

$SNEXBullishLow confidence
Context

StoneX Group director Thamodaran Dhamu R. bought 2,500 shares of SNEX for $161,206 on 2026-08-10 via an indirect holding.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing discloses an insider buy size and price, but provides no new company performance, guidance, or deal information that would reset valuation or risk.

Market effects

Minimal; insider buying in a single financial-services name does not materially change sector outlook.

None indicated.

None indicated.

Counterpoint

Director purchases can be driven by personal liquidity planning or diversification rather than a forward-looking view on the stock.

Key entities

  • StoneX Group Inc.

    Subject of the Form 4 insider transaction disclosure (SNEX).

  • Thamodaran Dhamu R.

    Director who purchased 2,500 shares of SNEX via indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.